BioSpace News Archive

Asklepios BioPharmaceutical, Inc. announced that the Company will present 11 abstracts at the upcoming American Society of Gene & Cell Therapy 25th Annual Meeting being held May 16 – 19, 2022 at the Walter E. Washington Convention Center in Washington, D.C.

The innovation community at The Oxford Science Park, one of Europe’s leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building.

GBS Inc. announced that Dr. Steven Boyages, GBS’ interim CEO and Chairman of the Board, along with other management team members will participate at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings.

CohBar, Inc. reported its financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress.

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, reported financial results for the first quarter ended March 31, 2022 and summarized recent business highlights.

Clarus Therapeutics Holdings, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, reported financial results for the first quarter of 2022.

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators, provided a business update and reported financial results for the quarter ended March 31, 2022.

Paratek Pharmaceuticals, Inc. announced that Evan Loh, M.D., chief executive officer, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference.

Acumen Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2022 and provided a business update.

Icosavax, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.